The development of non-viral vectors for KRAS-mutated cancer treatment has exponentially grown in the last decade [100,101,102], with the aim of (i) suppressing gene expression at the mRNA level (RNA interference strategies), (ii) artificially increasing gene expression, or (iii) correcting defective genes (gene modification). The gene discussed is KRAS; the disease is cancer.